Drug Trial Radar · NCT05495204
External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA
Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
141
Actual
Start
Aug 5, 2022
Primary completion
Feb 20, 2023
Study completion Feb 20, 2023
Sponsor
- Lead sponsor
- EpividianIndustry
- Sponsor type
- Industry
- Collaborators
- Theratechnologies; FIECON
- First posted
- Aug 10, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine clinical care in the OPERA cohort.
Conditions
- HIV-1-infection
Interventions
IbalizumabDrug
Participation in clinical trials vs. routine care in OPERA
Primary outcomes
What the sponsor says the trial is designed to measure.
- Viral suppressionTime frame: Week 24
- Viral suppressionTime frame: Week 48
- Viral suppressionTime frame: Week 60
- Viral suppressionTime frame: Week 96
- Viral undetectabilityTime frame: Week 24
- Viral undetectabilityTime frame: Week 48
- Viral undetectabilityTime frame: Week 60
- Viral undetectabilityTime frame: Week 96
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Epividian
Durham, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.